Foghorn Therapeutics(FHTX) - 2023 Q4 - Annual Results

Peter Kelleher, LifeSci Advisors (Investors) pkelleher@lifesciadvisors.com • Selective CBP and EP300 degrader preclinical data to be presented at AACR; IND-enabling studies for CBP degrader program planned to begin by end of 2024 • Foghorn anticipates at least six new INDs targeting significant oncology patient populations over the next four years, reflecting the continued productivity of its precision medicine platform • Cash, cash equivalents, and marketable securities of $234.1 million, as of December 31 ...